Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.52
MRK's Cash to Debt is ranked lower than
74% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. MRK: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s 10-Year Cash to Debt Range
Min: 0.32  Med: 0.73 Max: 2.45
Current: 0.52
0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked lower than
76% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s 10-Year Equity to Asset Range
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.44
0.34
0.53
Interest Coverage 7.75
MRK's Interest Coverage is ranked lower than
81% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. MRK: 7.75 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s 10-Year Interest Coverage Range
Min: 3.31  Med: 20.01 Max: 44.62
Current: 7.75
3.31
44.62
F-Score: 5
Z-Score: 3.27
M-Score: -3.14
WACC vs ROIC
4.96%
6.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.51
MRK's Operating margin (%) is ranked higher than
64% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. MRK: 12.51 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s 10-Year Operating margin (%) Range
Min: 5.15  Med: 22.79 Max: 43.77
Current: 12.51
5.15
43.77
Net-margin (%) 26.98
MRK's Net-margin (%) is ranked higher than
92% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. MRK: 26.98 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s 10-Year Net-margin (%) Range
Min: 1.87  Med: 19.58 Max: 47.03
Current: 26.98
1.87
47.03
ROE (%) 23.27
MRK's ROE (%) is ranked higher than
85% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. MRK: 23.27 )
Ranked among companies with meaningful ROE (%) only.
MRK' s 10-Year ROE (%) Range
Min: 1.52  Med: 33.15 Max: 48.6
Current: 23.27
1.52
48.6
ROA (%) 10.85
MRK's ROA (%) is ranked higher than
79% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. MRK: 10.85 )
Ranked among companies with meaningful ROA (%) only.
MRK' s 10-Year ROA (%) Range
Min: 0.79  Med: 15.50 Max: 18.45
Current: 10.85
0.79
18.45
ROC (Joel Greenblatt) (%) 98.23
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. MRK: 98.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.88  Med: 66.49 Max: 144.19
Current: 98.23
10.88
144.19
Revenue Growth (3Y)(%) -2.40
MRK's Revenue Growth (3Y)(%) is ranked lower than
74% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. MRK: -2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -16.5  Med: 3.60 Max: 21.4
Current: -2.4
-16.5
21.4
EBITDA Growth (3Y)(%) 19.10
MRK's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. MRK: 19.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.6  Med: 3.80 Max: 44.7
Current: 19.1
-17.6
44.7
EPS Growth (3Y)(%) 26.30
MRK's EPS Growth (3Y)(%) is ranked higher than
79% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. MRK: 26.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.7  Med: 6.70 Max: 73.8
Current: 26.3
-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MRK Guru Trades in Q2 2014

George Soros 86,800 sh (New)
Joel Greenblatt 126,844 sh (+3456.04%)
Ken Fisher 6,464,243 sh (+791.55%)
Jim Simons 795,534 sh (+305.47%)
Paul Tudor Jones 13,266 sh (+163.48%)
Pioneer Investments 4,256,501 sh (+81.49%)
Manning & Napier Advisors, Inc 380,192 sh (+7.55%)
Ruane Cunniff 4,609 sh (+4.54%)
Murray Stahl 48,271 sh (+0.46%)
James Barrow 22,793,207 sh (+0.24%)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Steven Cohen 17,200 sh (unchged)
Richard Snow 5,410 sh (unchged)
Mario Gabelli 160,316 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,434,531 sh (-0.68%)
Kahn Brothers 1,120,074 sh (-0.74%)
Tom Russo 4,386 sh (-3.31%)
Vanguard Health Care Fund 33,889,948 sh (-4.85%)
Bill Frels 107,546 sh (-5.84%)
Jeff Auxier 149,734 sh (-8.81%)
NWQ Managers 84,311 sh (-9.59%)
Dodge & Cox 35,960,137 sh (-10.01%)
First Eagle Investment 1,755,082 sh (-21.54%)
RS Investment Management 861,075 sh (-48.40%)
Jeremy Grantham 340,971 sh (-86.46%)
» More
Q3 2014

MRK Guru Trades in Q3 2014

Ray Dalio 14,141 sh (New)
Stanley Druckenmiller 329,600 sh (New)
Steven Cohen 321,100 sh (+1766.86%)
Joel Greenblatt 536,550 sh (+323.00%)
Paul Tudor Jones 31,725 sh (+139.15%)
Ruane Cunniff 4,784 sh (+3.80%)
Mario Gabelli 162,706 sh (+1.49%)
Robert Bruce 265,000 sh (+1.34%)
Ken Fisher 6,533,475 sh (+1.07%)
Brian Rogers 6,625,700 sh (unchged)
Pioneer Investments 4,327,974 sh (unchged)
RS Investment Management 861,075 sh (unchged)
Prem Watsa 12,000 sh (unchged)
George Soros Sold Out
James Barrow 22,769,088 sh (-0.11%)
NWQ Managers 83,811 sh (-0.59%)
Richard Snow 5,375 sh (-0.65%)
Manning & Napier Advisors, Inc 377,389 sh (-0.74%)
Bill Frels 106,735 sh (-0.75%)
Kahn Brothers 1,109,189 sh (-0.97%)
Jim Simons 787,634 sh (-0.99%)
Tom Russo 4,336 sh (-1.14%)
Vanguard Health Care Fund 33,420,748 sh (-1.38%)
Jeff Auxier 147,484 sh (-1.50%)
Dodge & Cox 35,057,668 sh (-2.51%)
Murray Stahl 46,821 sh (-3.00%)
Charles Brandes 2,320,288 sh (-4.69%)
First Eagle Investment 1,083,826 sh (-38.25%)
Signature Select Canadian Fund 163,400 sh (-45.44%)
Jeremy Grantham 118,890 sh (-65.13%)
» More
Q4 2014

MRK Guru Trades in Q4 2014

PRIMECAP Management 700,000 sh (New)
Joel Greenblatt 1,045,652 sh (+94.88%)
Paul Tudor Jones 53,076 sh (+67.30%)
Ray Dalio 20,541 sh (+45.26%)
Vanguard Health Care Fund 35,788,048 sh (+7.08%)
Manning & Napier Advisors, Inc 399,235 sh (+5.79%)
Ken Fisher 6,640,510 sh (+1.64%)
Bill Frels 107,684 sh (+0.89%)
James Barrow 22,856,934 sh (+0.39%)
NWQ Managers 83,828 sh (+0.02%)
Ruane Cunniff 4,784 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Richard Snow 5,375 sh (unchged)
Tom Russo 4,336 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Stanley Druckenmiller Sold Out
Murray Stahl 46,801 sh (-0.04%)
Jeff Auxier 147,334 sh (-0.10%)
Charles Brandes 2,306,840 sh (-0.58%)
Robert Bruce 259,400 sh (-2.11%)
Steven Cohen 311,600 sh (-2.96%)
Dodge & Cox 33,616,093 sh (-4.11%)
Kahn Brothers 1,052,807 sh (-5.08%)
Mario Gabelli 144,408 sh (-11.25%)
RS Investment Management 674,675 sh (-21.65%)
Pioneer Investments 3,201,729 sh (-26.02%)
Jim Simons 575,624 sh (-26.92%)
Jeremy Grantham 13,022 sh (-89.05%)
First Eagle Investment 9,050 sh (-99.16%)
» More
Q1 2015

MRK Guru Trades in Q1 2015

Jim Simons 1,194,169 sh (+107.46%)
PRIMECAP Management 1,385,000 sh (+97.86%)
Paul Tudor Jones 97,093 sh (+82.93%)
RS Investment Management 898,325 sh (+33.15%)
Vanguard Health Care Fund 40,096,948 sh (+12.04%)
Mario Gabelli 160,943 sh (+11.45%)
James Barrow 24,464,116 sh (+7.03%)
Ken Fisher 6,679,499 sh (+0.59%)
Robert Bruce 259,400 sh (unchged)
Richard Snow 5,375 sh (unchged)
Prem Watsa 12,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc 398,354 sh (-0.22%)
Signature Select Canadian Fund 161,300 sh (-1.29%)
Kahn Brothers 1,029,815 sh (-2.18%)
Bill Frels 105,158 sh (-2.35%)
Charles Brandes 2,221,791 sh (-3.69%)
NWQ Managers 76,286 sh (-9.00%)
Tom Russo 3,836 sh (-11.53%)
Murray Stahl 41,051 sh (-12.29%)
Pioneer Investments 2,753,869 sh (-13.99%)
Dodge & Cox 25,448,977 sh (-24.30%)
Jeremy Grantham 8,922 sh (-31.49%)
Joel Greenblatt 676,758 sh (-35.28%)
Jeff Auxier 40,324 sh (-72.63%)
Steven Cohen 77,800 sh (-75.03%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio
Over the duration of the third quarter the Vanguard Health Care Fund added two new stocks to its holdings. The fund now holds on to 89 stocks valued at $39.18 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.83
MRK's P/E(ttm) is ranked higher than
82% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. MRK: 14.83 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s 10-Year P/E(ttm) Range
Min: 6.67  Med: 17.59 Max: 139.89
Current: 14.83
6.67
139.89
Forward P/E 14.95
MRK's Forward P/E is ranked higher than
73% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. MRK: 14.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.20
MRK's PE(NRI) is ranked higher than
82% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. MRK: 15.20 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s 10-Year PE(NRI) Range
Min: 6.65  Med: 17.50 Max: 133.39
Current: 15.2
6.65
133.39
P/B 3.38
MRK's P/B is ranked higher than
51% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. MRK: 3.38 )
Ranked among companies with meaningful P/B only.
MRK' s 10-Year P/B Range
Min: 1.72  Med: 3.30 Max: 7.27
Current: 3.38
1.72
7.27
P/S 4.00
MRK's P/S is ranked lower than
55% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. MRK: 4.00 )
Ranked among companies with meaningful P/S only.
MRK' s 10-Year P/S Range
Min: 2.01  Med: 3.12 Max: 5.48
Current: 4
2.01
5.48
PFCF 18.72
MRK's PFCF is ranked higher than
80% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. MRK: 18.72 )
Ranked among companies with meaningful PFCF only.
MRK' s 10-Year PFCF Range
Min: 7.8  Med: 14.71 Max: 86.81
Current: 18.72
7.8
86.81
POCF 12.43
MRK's POCF is ranked higher than
84% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. MRK: 12.43 )
Ranked among companies with meaningful POCF only.
MRK' s 10-Year POCF Range
Min: 6.33  Med: 12.26 Max: 35.75
Current: 12.43
6.33
35.75
EV-to-EBIT 10.42
MRK's EV-to-EBIT is ranked higher than
83% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. MRK: 10.42 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5  Med: 18.80 Max: 104.2
Current: 10.42
8.5
104.2
PEG 3.80
MRK's PEG is ranked lower than
58% of the 245 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. MRK: 3.80 )
Ranked among companies with meaningful PEG only.
MRK' s 10-Year PEG Range
Min: 0.54  Med: 3.13 Max: 57.09
Current: 3.8
0.54
57.09
Shiller P/E 22.02
MRK's Shiller P/E is ranked higher than
73% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. MRK: 22.02 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s 10-Year Shiller P/E Range
Min: 8.26  Med: 13.87 Max: 25.71
Current: 22.02
8.26
25.71
Current Ratio 1.61
MRK's Current Ratio is ranked lower than
68% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. MRK: 1.61 )
Ranked among companies with meaningful Current Ratio only.
MRK' s 10-Year Current Ratio Range
Min: 1.07  Med: 1.53 Max: 3.7
Current: 1.61
1.07
3.7
Quick Ratio 1.34
MRK's Quick Ratio is ranked lower than
61% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. MRK: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s 10-Year Quick Ratio Range
Min: 0.8  Med: 1.20 Max: 3.44
Current: 1.34
0.8
3.44
Days Inventory 130.78
MRK's Days Inventory is ranked lower than
60% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. MRK: 130.78 )
Ranked among companies with meaningful Days Inventory only.
MRK' s 10-Year Days Inventory Range
Min: 50.6  Med: 129.85 Max: 332.33
Current: 130.78
50.6
332.33
Days Sales Outstanding 58.81
MRK's Days Sales Outstanding is ranked higher than
61% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. MRK: 58.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s 10-Year Days Sales Outstanding Range
Min: 44.42  Med: 56.06 Max: 92.3
Current: 58.81
44.42
92.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.14
MRK's Dividend Yield is ranked higher than
86% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. MRK: 3.14 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s 10-Year Dividend Yield Range
Min: 2.51  Med: 4.10 Max: 6.68
Current: 3.14
2.51
6.68
Dividend Payout 0.46
MRK's Dividend Payout is ranked higher than
70% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. MRK: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s 10-Year Dividend Payout Range
Min: 0.16  Med: 0.49 Max: 4.22
Current: 0.46
0.16
4.22
Dividend growth (3y) 4.30
MRK's Dividend growth (3y) is ranked lower than
59% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. MRK: 4.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
MRK' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 3.60 Max: 14.8
Current: 4.3
0
14.8
Yield on cost (5-Year) 3.74
MRK's Yield on cost (5-Year) is ranked higher than
81% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. MRK: 3.74 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3  Med: 4.89 Max: 7.97
Current: 3.74
3
7.97
Share Buyback Rate 1.80
MRK's Share Buyback Rate is ranked higher than
90% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. MRK: 1.80 )
Ranked among companies with meaningful Share Buyback Rate only.
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8  Med: 1.10 Max: -13
Current: 1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 41.22
MRK's Price/Tangible Book is ranked lower than
97% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. MRK: 41.22 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19  Med: 12.66 Max: 3735
Current: 41.22
3.19
3735
Price/Projected FCF 1.39
MRK's Price/Projected FCF is ranked higher than
77% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. MRK: 1.39 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s 10-Year Price/Projected FCF Range
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.39
0.75
3.04
Price/DCF (Earnings Based) 2.07
MRK's Price/DCF (Earnings Based) is ranked lower than
59% of the 51 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. MRK: 2.07 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.29
MRK's Price/Median PS Value is ranked higher than
53% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. MRK: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s 10-Year Price/Median PS Value Range
Min: 0.68  Med: 1.27 Max: 2.07
Current: 1.29
0.68
2.07
Price/Peter Lynch Fair Value 2.20
MRK's Price/Peter Lynch Fair Value is ranked higher than
50% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. MRK: 2.20 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.57  Med: 1.64 Max: 9.87
Current: 2.2
0.57
9.87
Price/Graham Number 5.17
MRK's Price/Graham Number is ranked lower than
75% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. MRK: 5.17 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s 10-Year Price/Graham Number Range
Min: 1.08  Med: 3.43 Max: 36.98
Current: 5.17
1.08
36.98
Earnings Yield (Greenblatt) (%) 9.82
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. MRK: 9.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 5.30 Max: 11.8
Current: 9.82
1
11.8
Forward Rate of Return (Yacktman) (%) 12.18
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. MRK: 12.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -6.2  Med: 6.00 Max: 22.1
Current: 12.18
-6.2
22.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:MRK.France, MRK.Argentina, 6MK.Germany, MRK.Chile, 0QAH.UK, MRCK34.Brazil, MRK.Switzerland, MRK.Mexico,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
Robert Bruce's Top Growth Stocks Apr 13 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 

More From Other Websites
Glenmark gets US regulator nod for cholesterol drug Jun 30 2015
Merck To Fully Acquire Israeli Quantum Materials Company Qlight Nanotech Jun 29 2015
Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28 Jun 26 2015
Merck Launches “More than a Mother” Campaign Aiming to Reduce Social Suffering of Infertile... Jun 23 2015
Merck Serono’s MSdialog Wins Readers Choice Category of 2015 Medical Design Excellence Award... Jun 22 2015
Merck Invests € 30 Million in New OLED Production Plant in Darmstadt Jun 19 2015
Merck Manual and MSD Manual Launch Global Medical Knowledge 2020 to Provide Free Access to Credible... Jun 17 2015
Merck Manuals Launches Global Medical Knowledge 2020 to Provide Free Access to Credible Medical... Jun 17 2015
Merck Serono Commits € 1.2 million to the Grant for Fertility Innovation (GFI) for 2015 / 16 Jun 17 2015
Innovative Laser Pigments: Merck at the Laser World of Photonics 2015 Jun 17 2015
Cancer immunomodulators market players Merck and Dynavax announce partnership for clinical trials Jun 16 2015
Merck Millipore’s Additions to the MAS-100® Product Family of Microbial Air Samplers Deliver... Jun 16 2015
Merck’s Acquisition of Sigma-Aldrich Receives Clearance from EU Regulators – Approvals Also... Jun 15 2015
Merck Millipore Expands Provantage® Biodevelopment Services with Addition of Provantage® Clone... Jun 15 2015
Merck Millipore Introduces the Mobius® 2000 Liter Single-Use Bioreactor with Industry-leading... Jun 15 2015
Merck Serono: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE... Jun 14 2015
Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their... Jun 11 2015
Merck Serono Wins Two Red Dot Design Awards 2015 for High Quality Design of Fertility Pens Jun 11 2015
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4,... Jun 10 2015
TECOS, the Trial Evaluating Cardiovascular Outcomes with JANUVIA® (Sitagliptin), Met Primary... Jun 10 2015
Consumerization Drives Growth at Merck Consumer Health Jun 09 2015
Consumerization Drives Growth at Merck Consumer Health Jun 09 2015
Giant Study Boosts Januvia, Merck's $6 Billion Drug Jun 08 2015
TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in... Jun 08 2015
This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says Jun 08 2015
Autoimmune Drugs to Drive Big Pharma Higher in Coming Years Jun 08 2015
Boston's Intarcia now one step closer to upending type 2 diabetes market Jun 08 2015
Illumina, Merck KGaA, Darmstadt, Germany, and Genea Form the Global Fertility Alliance for... Jun 08 2015
Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises Jun 08 2015
UPDATE: Gilead Sciences: What Game Theory Teaches Us About Hepatitis C Jun 05 2015
Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog Jun 04 2015
Merck's Quest To Revive The Market For Insomnia Drugs Jun 04 2015
Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in... Jun 03 2015
Amgen: The Quiet Winner Jun 03 2015
Why Sigma-Aldrich’s stock is falling Jun 03 2015
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate Jun 02 2015
Tests for new cancer drugs not reliable enough, doctors say Jun 02 2015
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog Jun 02 2015
FDA Grants Priority Review for Merck Lung Cancer Treatment Jun 01 2015
Merck KGaA sees immunotherapy drug holding its own in cancer race Jun 01 2015
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab),... Jun 01 2015
Bristol-Myers Squibb: Recovering Jun 01 2015
Puma Biotech is an opportunity: Pro Jun 01 2015
Merck's fight against cancer Jun 01 2015
UPDATE 1-U.S. bird flu causes egg shortage, emergency measures May 23 2015
Germany's Merck expects drug division to drive growth-Euro am Sonntag May 23 2015
U.S. bird flu causes egg shortage, emergency measures May 22 2015
U.S. bird flu causing egg squeeze, emergency measures May 22 2015
U.S. FDA warns on newer class of type 2 diabetes drugs May 15 2015
Supreme Court bars Glenmark from selling Merck drug copies May 15 2015
Supreme Court bars Glenmark from selling Merck drug copies May 15 2015
BUZZ-Cancer drugs: Roche impresses in immunotherapy race May 14 2015
As Ebola disappears, no useful data seen from vaccine trials -WHO May 12 2015
Under pressure, FDA to hold public meeting on off-label use May 07 2015
Global cancer drug spending hits $100 billion in 2014 - IMS Health May 05 2015
Global cancer drug spending hits $100 billion in 2014-IMS Health May 05 2015
MEDIA-Global annual spending on cancer drugs surges to $100 bln - FT May 04 2015
New meds help drugmakers weather strong dollar, other issues Apr 28 2015
US STOCKS-Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple Apr 28 2015
AstraZeneca falls on diabetes worries Apr 28 2015
US STOCKS-Wall St edges up with Merck, IBM; Nasdaq slips with Apple Apr 28 2015
Stocks mostly higher as company earnings reports pour in Apr 28 2015
Pfizer, despite dollar and generics fight, still impresses Apr 28 2015
Merck hurdles Wall Street forecasts Apr 28 2015
US STOCKS-Wall St reverses course to trade higher Apr 28 2015
FTSE falls after weak corporate updates, U.S. data Apr 28 2015
Britain's FTSE falls after weak corporate updates, U.S. data Apr 28 2015
Stocks fluctuate as company earnings reports pour in Apr 28 2015
Britain's FTSE falls after weak corporate updates, U.S. data Apr 28 2015
US stocks fall despite strong Merck, Apple earnings Apr 28 2015
Stocks move lower as US company earnings reports pour in Apr 28 2015
US STOCKS-Wall St fall as earnings disappoint Apr 28 2015
Merck pulls up Dow as Apple investors cautious Apr 28 2015
Merck tops Street 1Q forecasts Apr 28 2015
GSK shingles vaccine shows benefits across all age groups Apr 28 2015
Studies: Merck drug Keytruda effective against 3 cancers Apr 19 2015
FDA panel wants heart failure risk on AstraZeneca drugs Apr 14 2015
Walker signs deal with German researchers, meets with Merck Apr 13 2015
Data suggests AstraZeneca drug may increase death rate - U.S FDA Apr 10 2015
Venture capitalists ride biotech wave one drug at a time Apr 10 2015
Merck's potential HCV drug gets special FDA designation Apr 08 2015
Merck board OKs additional $10 billion stock buyback plan Mar 24 2015
Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin Mar 20 2015
India caps prices of 52 more "essential" drugs - NPPA Dec 12 2014
Pfizer dampens Astra bid hopes with German Merck cancer deal Nov 17 2014
Germany's Merck to buy Sigma-Aldrich for $17 bln Sep 22 2014
Merck licenses experimental psoriasis drug to Sun Pharma Sep 17 2014
Merck KGaA agrees to market Lupin drugs in emerging countries Sep 16 2014
Merck aims to hike revenues in China to 1 bln eur by 2018 Jul 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK